Andrew Biankin
Professor Andrew Biankin is the Regius Chair of Surgery at the University of Glasgow, a Cancer Research UK Clinician Scientist, a Wellcome Trust Senior Investigator, a Fellow of the Royal Society of Edinburgh and the Academy of Medical Sciences. He is the Director of the Wolfson Wohl Cancer Research Centre which is focused on precision oncology. He has leadership roles in national and international consortia in cancer genomics and therapeutic development. He has authored over 160 articles in major journals including seminal works on cancer, genomics and precision medicine.
1. Project: 'ASTERIX: Adaptive Salvage Treatment based on Endotype-directed anti-viRals and Immunomodulation – an NHS framework to enable research and clinical trials'
Summary: Scotland is well-positioned to contribute to the urgent need for COVID-19 treatments. To do this they need to understand the disease and quickly bring new treatments to Scottish patients in trials. The ASTERIX framework will be integrated into clinical systems so that frontline staff are not burdened, using repurposed NHS infrastructure and staff. ASTERIX will allow to learn quickly, while under huge clinical pressures, and streamline patients into trials. This learning will include how to treat COVID-19 and how to ensure that critical trial results are robust and relevant to Scottish patients.
The ASTERIX study is led by
Professor Kevin Blyth, NHSGGC, University of Glasgow
Professor Iain McInnes, University of Glasgow
Co-investigator and institutions:
Professor Andrew Biankin, University of Glasgow
Professor Rob Jones, CRUK Glasgow CTU, University of Glasgow
Professor Emma Thomson, MRC University of Glasgow Centre of Virus Research
Dr Janet Scott, MRC University of Glasgow Centre of Virus Research
Professor Carl Goodyear, University of Glasgow
Clare Orange, NHSGGC Biorepository
Dr David Lowe, National Clinical Lead for Digital Health & Clinical Informatics DHI, NHSGGC
Dr Michael Murphy, Microbiology, NHSGGC
Funder: Chief Scientist Office
Total award: £17,000
2. Project: 'Viral and Immunological Correlates of Clinical Severity and Response to Anti-Viral Therapy for COVID-19'
Project summary: The clinical outcome of COVID-19 is ultimately determined by viral replication in the face of the host immunity. The latter can either control viral infection or exacerbate disease due to uncontrolled inflammatory processes that damages tissues. Hence, in order to establish the efficacy of antiviral therapies and determine whether stratification can aid clinical decisions in COVID19 patients, the study needs to identify correlates of disease severity and response to treatment. This proposal aims to fully determine the dynamic viral and immunological changes occurring during the different clinical stages of COVID-19. They will use a clinical trial for Favipiravir (GETAFIX, GLA3), an antiviral drug as their test case to develop their biomarkers but can roll this project out to support other trials within ASTERIX (GLA2).
The study is led by:
Professor Carl Goodyear, University of Glasgow
Co-investigators and institutions at University of Glasgow:
Professor Massimo Palmarini
Professor Iain McInnes
Professor Brian Willett
Professor Emma Thomson
Professor Gerard Graham
Professor Paul Garside
Professor Naveed Sattar
Professor Andrew Biankin
Professor David Robertson
Dr Janet Scott
Dr Antonia Ho
Dr Thomas Otto
Dr Ana Da Silva Filipe
Co-investigators and institutions at GGCHB NHS:
Dr Michael Murphy
Funder: Chief Scientist Office
Total award: £319,473
1. Project: 'ASTERIX: Adaptive Salvage Treatment based on Endotype-directed anti-viRals and Immunomodulation – an NHS framework to enable research and clinical trials'
Summary: Scotland is well-positioned to contribute to the urgent need for COVID-19 treatments. To do this they need to understand the disease and quickly bring new treatments to Scottish patients in trials. The ASTERIX framework will be integrated into clinical systems so that frontline staff are not burdened, using repurposed NHS infrastructure and staff. ASTERIX will allow to learn quickly, while under huge clinical pressures, and streamline patients into trials. This learning will include how to treat COVID-19 and how to ensure that critical trial results are robust and relevant to Scottish patients.
The ASTERIX study is led by
Professor Kevin Blyth, NHSGGC, University of Glasgow
Professor Iain McInnes, University of Glasgow
Co-investigator and institutions:
Professor Andrew Biankin, University of Glasgow
Professor Rob Jones, CRUK Glasgow CTU, University of Glasgow
Professor Emma Thomson, MRC University of Glasgow Centre of Virus Research
Dr Janet Scott, MRC University of Glasgow Centre of Virus Research
Professor Carl Goodyear, University of Glasgow
Clare Orange, NHSGGC Biorepository
Dr David Lowe, National Clinical Lead for Digital Health & Clinical Informatics DHI, NHSGGC
Dr Michael Murphy, Microbiology, NHSGGC
Funder: Chief Scientist Office
Total award: £17,000
2. Project: 'Viral and Immunological Correlates of Clinical Severity and Response to Anti-Viral Therapy for COVID-19'
Project summary: The clinical outcome of COVID-19 is ultimately determined by viral replication in the face of the host immunity. The latter can either control viral infection or exacerbate disease due to uncontrolled inflammatory processes that damages tissues. Hence, in order to establish the efficacy of antiviral therapies and determine whether stratification can aid clinical decisions in COVID19 patients, the study needs to identify correlates of disease severity and response to treatment. This proposal aims to fully determine the dynamic viral and immunological changes occurring during the different clinical stages of COVID-19. They will use a clinical trial for Favipiravir (GETAFIX, GLA3), an antiviral drug as their test case to develop their biomarkers but can roll this project out to support other trials within ASTERIX (GLA2).
The study is led by:
Professor Carl Goodyear, University of Glasgow
Co-investigators and institutions at University of Glasgow:
Professor Massimo Palmarini
Professor Iain McInnes
Professor Brian Willett
Professor Emma Thomson
Professor Gerard Graham
Professor Paul Garside
Professor Naveed Sattar
Professor Andrew Biankin
Professor David Robertson
Dr Janet Scott
Dr Antonia Ho
Dr Thomas Otto
Dr Ana Da Silva Filipe
Co-investigators and institutions at GGCHB NHS:
Dr Michael Murphy
Funder: Chief Scientist Office
Total award: £319,473
Country:
United Kingdom